gv 1001 telomerase peptide
Advanced Melanoma
Herlev Hospitalprotein_peptidePhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 73/ 100
Competitive context
35 Active assets in the Advanced Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PROPRANOLOL Sarah Weiss | Phase 2/3 | B |
Tuvonralimab Hebei Medical University Fourth Hospital | Phase 4 | B |
Bcd-263 Biocad | Phase 3 | B |
Iparomlimab Hebei Medical University Fourth Hospital | Phase 4 | B |
Autogene Cevumeran Genentech, Inc. | Phase 2 | B |
View all 50 →
Same molecule, other indications
gv 1001 telomerase peptide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →